Clinical trial
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated…
NCT00289640 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00289640 |
|---|---|
| Title | Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
| Official title | A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Medarex Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | ipilimumab (MDX-010, BMS-734016), Ipilimumab |
| Enrollment | 210 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Feb 10, 2006 |
| Last update posted | Mar 2, 2010 |
| Countries | Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: